Skip to content

Nutraceuticals and Drug Treatment in Frail Older Adults

Cognitive and Physical Impairment in Frail Older Adults

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04962841
Enrollment
485
Registered
2021-07-15
Start date
2020-04-01
Completion date
2023-04-01
Last updated
2022-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Frailty

Keywords

frailty, cognitive impairment, physical impairment, older adults

Brief summary

Frailty is a multidimensional condition due to reserve loss leading to physical and cognitive impairment that is very common in older adults; in fact, its incidence increases with age. Frail older adults present a high risk of adverse events such as disability, hospitalization and mortality. It is very important to check comorbidities and complications to reduce the incidence of cognitive and physical impairment.

Detailed description

Frailty is a multidimensional condition due to reserve loss leading to physical and cognitive impairment that is very common in older adults; in fact, its incidence increases with age. Frail older adults present a high-risk of adverse events such as disability, hospitalization and mortality. It is very important to check comorbidities and complications to reduce the incidence of cognitive and physical impairment; hence, clinical evaluation is the main goal to get an early diagnosis and a timely treatment for cognitive impairment. Considering this background, the study will investigate the effects of nutraceuticals and drug treatment on cognitive impairment in frail older adults. In this scenario, global cognitive function will be evaluated with Mini Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) test and physical impairment with the Fried criteria and 5-metres gait speed test.

Interventions

To observe the effect on cognitive and physical impairment.

Sponsors

University of Campania Luigi Vanvitelli
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum

Inclusion criteria

* age \> 65 years; * a frailty status.

Exclusion criteria

* age \< 65 years. * no frailty status. * left ventricular ejection fraction \<25%, with previous myocardial infarction or previous PPCI or/and coronary by-pass grafting.

Design outcomes

Primary

MeasureTime frameDescription
Montreal Cognitive Assessment (MoCA)July 2021Global cognitive impairment

Secondary

MeasureTime frameDescription
5 metres gait speed testJuly 2021Physical impairment

Other

MeasureTime frame
Correlation between MMSE/MoCA and 5 metres gait speed testJuly 2021

Countries

Italy

Contacts

Primary ContactPasquale Mone, MD
pasquale.mone@unicampania.it0823275386
Backup ContactAntonella Pansini, MD
apansini@asl.it0823275386

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026